Relay Therapeutics

Home
United States
Cambridge, MA
Relay Therapeutics

Directions Website

Integrating leading-edge computational and experimental science to transform human health.

10/16/2026

Congratulations to the Vascular Malformations Centre at Cliniques universitaires Saint-Luc on 35 years of caring for people living with !

We were honored to join in Belgium this past weekend for a day of education, exchange, and celebration. It was a privilege to connect with the healthcare professionals, patients and families.

Thank you to VASCAPA.asbl and the Centre team for bringing everyone together. Here's to many more advancements for the vascular anomalies community.

10/14/2026

We were thrilled to return to Arkansas this year for a family event hosted by the Association of Pediatric Hematology/Oncology Nurses (APHON). Our team enjoyed spending the day with individuals and families living with and hearing their experiences firsthand. Time with this community continues to deepen our understanding of the effects PIK3CA-driven VAs can have on daily life and reaffirms our commitment to the patients and families. Thank you to APHON for another impactful family day!

10/13/2026

If you or someone you know has been diagnosed with a PIK3CA-driven vascular malformation, we invite you to learn more about a new clinical trial.

Relay Therapeutics is enrolling individuals in the ReInspire Study, a clinical trial evaluating an investigational therapy for people with lymphatic malformations, PIK3CA-related overgrowth spectrum (PROS) conditions such as Klippel Trenaunay syndrome, CLOVES syndrome, or FAVA, and other PIK3CA-driven vascular malformations.

Learn more about this study and see if you may be eligible. https://reinspirestudy.com/

09/29/2026

A diagnosis doesn’t just affect the body. It changes how we think, connect, and plan for the future.

ReDiscover-2 is a Phase 3 clinical trial evaluating an investigational therapy for people living with PIK3CA-mutated HR+/HER2- metastatic . By participating in clinical studies, patients help advance research and potential future treatment options. Learn more about the study below. www.rediscover2.com

09/15/2026

Are you or a loved one living with a lymphatic malformation or PIK3CA-related overgrowth spectrum (PROS) condition, such as Klippel-Trenaunay syndrome, CLOVES syndrome, or FAVA?

You may be eligible to participate in the ReInspire Study, a clinical trial evaluating an investigational therapy from Relay Therapeutics.

Visit the study website to learn more about eligibility requirements and if participation may be right for you. https://reinspirestudy.com/

09/03/2026

There’s nothing quite like that moment when the team crowds around a desk to see promising experimental results.

At Relay Tx, we're grateful for a research team that is committed to tackling some of the toughest targets in drug discovery. This is what it means to work on something that matters.

09/01/2026

Living with cancer can be overwhelming physically, emotionally, and mentally for both the patient and their loved ones.

At Relay Therapeutics, we are studying an investigational medicine for people with PIK3CA-mutated HR+/HER2- metastatic . The ReDiscover-2 Phase 3 clinical trial is now enrolling eligible patients. Explore if participation may be an option for you or a loved one. https://rediscover2.com/

08/20/2026

: In February 2026, we announced that the U.S. FDA granted zovegalisib Breakthrough Therapy Designation for PIK3CA-mutant, HR+/HER2- advanced . The designation was supported by robust clinical data from our Phase 1/2 ReDiscover trial evaluating zovegalisib in combination with fulvestrant.

🔗 Visit our website, linked in our bio, for more information.

08/18/2026

Are you living with a PIK3CA-driven vascular malformation, such as lymphatic malformation, or a PIK3CA-Related Overgrowth Spectrum condition like Klippel-Trenaunay syndrome, CLOVES syndrome, or FAVA? Learn more about an open clinical trial evaluating a potential new treatment option. https://reinspirestudy.com/

Swipe to learn more about the PIK3CA gene and how it plays a role in certain types of vascular malformations.

08/05/2026

If you or someone you know has been diagnosed with PIK3CA-mutated HR+/HER2- metastatic , we want to help you learn more about potential treatment options.

Relay Therapeutics is enrolling patients in the ReDiscover-2 study, a Phase 3 clinical trial evaluating an investigational therapy for people with metastatic breast cancer.

Learn more about this study and see if you may be eligible. https://rediscover2.com/

Address

60 Hampshire Street
Cambridge, MA
02139

Website

http://www.relaytx.com/

Alerts

Be the first to know and let us send you an email when Relay Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

In A Minute Security Services
459 Broadway Suite B3, Everett

Want your business to be the top-listed business in Cambridge?